Interview with Quotient Sciences CEO, Thierry Van Nieuwenhove: On Growth and Role in Accelerating Drug Development

Thierry Van Nieuwenhove , CEO at Quotient Sciences, discusses unique factors that set the company apart as a novel outsourcing provider of integrated #CDMO and #CRO drug development services and growth plans aimed at enhancing the delivery of programs for our customers. Read more from this interview on our website.

Ultimately, no matter how a customer chooses to work with us and where they work with us, I want our customers to know that the dedication and expertise of our more than 1,300 colleagues will help deliver success.

Since joining Quotient Sciences in October 2023, what have been your impressions of the company so far??

TVN: It was humbling to see the impact that Quotient Sciences’ Translational Pharmaceutics? platform has delivered for customers such as Ensysce Biosciences , Day One Biopharmaceuticals , Oxilio , and many others over the past 16 years. The relationships that we have built, both with small biotechs and with large Fortune 100 pharmaceutical companies, have been impressive to see.

I am proud to be part of a company that is not only delivering drug development in a unique way for our customers but with a track record of impactful time and cost savings that ultimately helps increase the success rate of new medicine approvals.?

How does Translational Pharmaceutics? add value to client programs?

TVN: Translational Pharmaceutics? integrates formulation development, on-demand and adaptive GMP manufacturing, healthy volunteer clinical testing and data analysis within a single organization. A unified project management team helps coordinate all activities.

In that sense, Translational Pharmaceutics? transforms the traditional outsourcing model, where a combination of CDMOs and CROs are usually required with handovers at different points throughout a drug program.

What are some of the Company’s top priorities this year?

TVN: Looking ahead, the expansion of our Translational Pharmaceutics? platform in the US remains a key objective. Applying Translational Pharmaceutics? under US regulations complements capabilities offered from our Nottingham, UK facility. This gives clients flexibility in where they choose to work, so they can realize the benefits that Translational Pharmaceutics? delivers.

Although 2023 was a difficult year for the entire industry, CDMOs such as Quotient Sciences continued to thrive by providing innovative solutions, a deep understanding of science, and strategic partnership to clients. 2024 has showed us signs of recovery, with some increased biotech industry funding again to support the growing number of new molecules in the development pipelines.?

Ultimately, no matter how a customer chooses to work with us and where they work with us, I want our customers to know that the dedication and expertise of our more than 1,300 colleagues will help deliver success.